Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yan's Jiangzhi Decoction
- Development stage
- Preclinical
- Lead developer
- Shanghai Shen Kang Hospital Development Center
- Administration
- Oral
01
Overview
Yan's Jiangzhi Decoction is a Traditional Chinese Medicine (TCM) herbal formulation currently undergoing a prospective randomized controlled trial for the treatment of dyslipidemia complicated with carotid atherosclerosis. While its specific mechanism is not detailed in the provided context, similar "Jiangzhi Decoction" formulations have been shown to regulate nuclear receptor transcription and lipid metabolism, affecting targets such as PPARα, LXRα, and HNF4α, leading to reduced lipid accumulation and regulated cholesterol and triglyceride levels.
- Other names
- Yanshi Jiangzhi Prescription颜氏降脂方
02
Targets
HNF4A (Hepatocyte nuclear factor 4 alpha)NR1H3 (Liver X receptor beta)PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on Yan's Jiangzhi Decoction.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yan's Jiangzhi Decoction.